Moreover, these findings here are in agreement with the role of FGFR3 in gliomas, particularly in the consequences of FRFR3-TACC3 fusion events, where the fusion genes have cancer promoting roles and could be inhibited to gain clinical improvement when treated with JNJ-42756493 [21]. This evidence concerns the gene FGFR3 and central nervous system cancer.